Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement

Anoop K Enjeti¹, Rishu Agarwal², Piers Blombery³, Lynette Chee³, Chong Chyn Chua⁴, Andrew Grigg⁵, Nada Hamad⁶, Harry Iland⁷, Steven Lane⁸, Andrew Perkins⁹, Deepak Singhal¹⁰, Courtney Tate¹¹, Ing Soo Tiong¹², David M Ross¹³

Affiliations

¹ Australasian Leukaemia and Lymphoma Group, Australia; Department of Haematology, Calvary Mater Hospital, Waratah, NSW, Australia; New South Wales Health Pathology, John Hunter Hospital New Lambton Heights, NSW, Australia; University of Newcastle, Callaghan, NSW, Australia. Electronic address: Anoop.Enjeti@calvarymater.org.au.
² Australasian Leukaemia and Lymphoma Group, Australia; Austin Pathology, Melbourne, Vic, Australia.
³ Australasian Leukaemia and Lymphoma Group, Australia; Department of Clinical Haematology, The Royal Melbourne Hospital, Vic, Australia; Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; Department of Medicine, The University of Melbourne, Parkville, Vic, Australia.
⁴ Australasian Leukaemia and Lymphoma Group, Australia; Department of Clinical Haematology, Northern Hospital, Melbourne, Vic, Australia.
⁵ Australasian Leukaemia and Lymphoma Group, Australia; Department Clinical Haematology, Austin Hospital Melbourne, Vic, Australia.
⁶ Australasian Leukaemia and Lymphoma Group, Australia; Department of Haematology, St Vincent's Hospital School of Medicine, University of Notre Dame, NSW, Australia; St Vincent's Clinical School Sydney, University of New South Wales, NSW, Australia.
⁷ Australasian Leukaemia and Lymphoma Group, Australia; Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
⁸ Australasian Leukaemia and Lymphoma Group, Australia; Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia; Cancer Program, QIMR Berghofer Medical Research Institute Brisbane, Qld, Australia.
⁹ Australasian Leukaemia and Lymphoma Group, Australia; Head of Genomic Medicine, Alfred Health, Melbourne, Vic, Australia.
¹⁰ Australasian Leukaemia and Lymphoma Group, Australia; Haematology Directorate, SA Pathology and Royal Adelaide Hospital, Adelaide, SA, Australia.
¹¹ Australasian Leukaemia and Lymphoma Group, Australia; Department of Clinical Haematology, Princess Alexandra Hospital, Queensland Health, Brisbane, Qld, Australia; University of Queensland, Qld, Australia.
¹² Australasian Leukaemia and Lymphoma Group, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Vic, Australia; Monash University, Melbourne, Vic, Australia.
¹³ Australasian Leukaemia and Lymphoma Group, Australia; Haematology Directorate, SA Pathology and Royal Adelaide Hospital, Adelaide, SA, Australia; Department of Haematology, Flinders University and Medical Centre, Adelaide, SA, Australia.

PMID: 35461716
DOI: 10.1016/j.pathol.2022.03.002

Free article

Review

Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement

Anoop K Enjeti et al. Pathology. 2022 Jun.

Free article

. 2022 Jun;54(4):389-398.

doi: 10.1016/j.pathol.2022.03.002. Epub 2022 Apr 20.

Authors

Affiliations

¹ Australasian Leukaemia and Lymphoma Group, Australia; Department of Haematology, Calvary Mater Hospital, Waratah, NSW, Australia; New South Wales Health Pathology, John Hunter Hospital New Lambton Heights, NSW, Australia; University of Newcastle, Callaghan, NSW, Australia. Electronic address: Anoop.Enjeti@calvarymater.org.au.
² Australasian Leukaemia and Lymphoma Group, Australia; Austin Pathology, Melbourne, Vic, Australia.
³ Australasian Leukaemia and Lymphoma Group, Australia; Department of Clinical Haematology, The Royal Melbourne Hospital, Vic, Australia; Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; Department of Medicine, The University of Melbourne, Parkville, Vic, Australia.
⁴ Australasian Leukaemia and Lymphoma Group, Australia; Department of Clinical Haematology, Northern Hospital, Melbourne, Vic, Australia.
⁵ Australasian Leukaemia and Lymphoma Group, Australia; Department Clinical Haematology, Austin Hospital Melbourne, Vic, Australia.
⁶ Australasian Leukaemia and Lymphoma Group, Australia; Department of Haematology, St Vincent's Hospital School of Medicine, University of Notre Dame, NSW, Australia; St Vincent's Clinical School Sydney, University of New South Wales, NSW, Australia.
⁷ Australasian Leukaemia and Lymphoma Group, Australia; Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
⁸ Australasian Leukaemia and Lymphoma Group, Australia; Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia; Cancer Program, QIMR Berghofer Medical Research Institute Brisbane, Qld, Australia.
⁹ Australasian Leukaemia and Lymphoma Group, Australia; Head of Genomic Medicine, Alfred Health, Melbourne, Vic, Australia.
¹⁰ Australasian Leukaemia and Lymphoma Group, Australia; Haematology Directorate, SA Pathology and Royal Adelaide Hospital, Adelaide, SA, Australia.
¹¹ Australasian Leukaemia and Lymphoma Group, Australia; Department of Clinical Haematology, Princess Alexandra Hospital, Queensland Health, Brisbane, Qld, Australia; University of Queensland, Qld, Australia.
¹² Australasian Leukaemia and Lymphoma Group, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Vic, Australia; Monash University, Melbourne, Vic, Australia.
¹³ Australasian Leukaemia and Lymphoma Group, Australia; Haematology Directorate, SA Pathology and Royal Adelaide Hospital, Adelaide, SA, Australia; Department of Haematology, Flinders University and Medical Centre, Adelaide, SA, Australia.

PMID: 35461716
DOI: 10.1016/j.pathol.2022.03.002

Abstract

This review aims to provide an expert consensus statement to address the role of gene-panel testing in the diagnosis, prognosis and management of adult myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes (MDS/MPN) in Australia. This consensus statement was developed by an expert group, actively involved in gene panel testing in the area of MDS/MPN in Australia. This work was led by the chairs of the MDS (A/Prof A. Enjeti) and MPN (A/Prof D. Ross) working parties of the Australasian Leukaemia and Lymphoma Group (ALLG). The authors were selected after an expression of interest process on the basis of active laboratory involvement in gene panel testing, a specific demonstrated interest in MDS/MPN and/or publication record in this field. The authors were then allocated sections for literature review to identify the specific genes of interest for each MDS/MPN entity. At least two authors reviewed each section and an overarching diagnostic algorithm was developed by a consensus amongst all authors.

Keywords: Myelodysplasia; NGS; consensus; gene panel; myeloproliferative neoplasms.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement

Affiliations

Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement

Authors

Affiliations

Abstract

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous